Mitsogianni Maria, Trontzas Ioannis P, Gomatou Georgia, Ioannou Stephanie, Syrigos Nikolaos K, Kotteas Elias A
Oncology Unit, 'Sotiria' General Hospital, Athens School of Medicine, Athens 11527, Greece.
Oncol Lett. 2021 Apr;21(4):287. doi: 10.3892/ol.2021.12548. Epub 2021 Feb 12.
Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer has been historically associated with an aggressive disease course with common distant metastasis and poor prognosis. HER2-targeting therapies have significantly changed treatment and drastically improved outcomes for this group of patients. However, primary or acquired resistance to anti-HER2 regimens leads almost universally to disease progression, often with difficult to treat central nervous system (CNS) metastases. The current review summarized the existing therapeutic options for HER2-positive metastatic disease in the first, second and further line setting. Furthermore, novel agents currently under development were presented, which have demonstrated encouraging results in heavily pretreated patients or specific subgroups, such as HR-positive/HER2-positive tumors and CNS disease.
人表皮生长因子受体2（HER2）过表达的乳腺癌在历史上一直与侵袭性病程相关，常发生远处转移且预后较差。针对HER2的疗法显著改变了治疗方式，并极大地改善了这组患者的治疗效果。然而，对抗HER2方案的原发性或获得性耐药几乎普遍导致疾病进展，且常伴有难以治疗的中枢神经系统（CNS）转移。本综述总结了HER2阳性转移性疾病一线、二线及后续治疗中的现有治疗选择。此外，还介绍了目前正在研发的新型药物，这些药物在经过大量预处理的患者或特定亚组中，如激素受体（HR）阳性/HER2阳性肿瘤和CNS疾病，已显示出令人鼓舞的结果。
